MedTrace Logo

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

NCT00406601 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2010-09-02

No results posted yet for this study

Summary

The aim of this study (\*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients.

(\*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Sorafenib (BAY-43-9006)

800 mg/die orally on a continuous basis

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Armando Santoro, MD · Istituto Clinico Humanitas

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2010-06-30
Completion
2010-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406601 on ClinicalTrials.gov